Chronopharmacological study of bunazosin hydrochloride in healthy subjects. 1989

Y Kumagai, and A Fujimura, and H Nakashima, and T Shitoh, and K Sugimoto, and H Oribe, and A Ebihara
Department of Clinical Pharmacology, Medical College of Oita, Japan.

Bunazosin, an alpha-1 adrenoreceptor blocking agent, was given orally to six healthy subjects in the morning or in the evening in order to examine the time-dependent variations in the pharmacological effects of the drug. The study was carried out on four occasions in a placebo controlled cross-over design. No significant change was observed in blood pressure either after the morning or the evening dosage. Finger skin blood flow (FSBF) assessed by laser Doppler flowmetry increased significantly after the morning dosage, but not after the evening trial. The plasma concentration of bunazosin in the morning in general had a tendency to be greater than that in the evening. A significant correlation was observed between the plasma concentrations and the increments in the FSBF. These results indicate that the pharmacological effects of bunazosin are greater following morning dosage. The present study supports the concept that the time-dependent differences in the effect of bunazosin are, at least, caused by the time-dependent changes in plasma drug concentration.

UI MeSH Term Description Entries
D008297 Male Males
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D012039 Regional Blood Flow The flow of BLOOD through or around an organ or region of the body. Blood Flow, Regional,Blood Flows, Regional,Flow, Regional Blood,Flows, Regional Blood,Regional Blood Flows
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005385 Fingers Four or five slender jointed digits in humans and primates, attached to each HAND. Finger
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000317 Adrenergic alpha-Antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. Adrenergic alpha-Receptor Blockaders,alpha-Adrenergic Blocking Agents,alpha-Adrenergic Receptor Blockaders,alpha-Blockers, Adrenergic,Adrenergic alpha-Blockers,alpha-Adrenergic Antagonists,alpha-Adrenergic Blockers,Adrenergic alpha Antagonists,Adrenergic alpha Blockers,Adrenergic alpha Receptor Blockaders,Agents, alpha-Adrenergic Blocking,Antagonists, alpha-Adrenergic,Blockaders, Adrenergic alpha-Receptor,Blockaders, alpha-Adrenergic Receptor,Blockers, alpha-Adrenergic,Blocking Agents, alpha-Adrenergic,Receptor Blockaders, alpha-Adrenergic,alpha Adrenergic Antagonists,alpha Adrenergic Blockers,alpha Adrenergic Blocking Agents,alpha Adrenergic Receptor Blockaders,alpha Blockers, Adrenergic,alpha-Antagonists, Adrenergic,alpha-Receptor Blockaders, Adrenergic
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.

Related Publications

Y Kumagai, and A Fujimura, and H Nakashima, and T Shitoh, and K Sugimoto, and H Oribe, and A Ebihara
January 1988, International journal of clinical pharmacology research,
Y Kumagai, and A Fujimura, and H Nakashima, and T Shitoh, and K Sugimoto, and H Oribe, and A Ebihara
January 2008, Drug metabolism and pharmacokinetics,
Y Kumagai, and A Fujimura, and H Nakashima, and T Shitoh, and K Sugimoto, and H Oribe, and A Ebihara
July 1991, The British journal of ophthalmology,
Y Kumagai, and A Fujimura, and H Nakashima, and T Shitoh, and K Sugimoto, and H Oribe, and A Ebihara
November 1989, Kokyu to junkan. Respiration & circulation,
Y Kumagai, and A Fujimura, and H Nakashima, and T Shitoh, and K Sugimoto, and H Oribe, and A Ebihara
August 2021, International journal of clinical pharmacology and therapeutics,
Y Kumagai, and A Fujimura, and H Nakashima, and T Shitoh, and K Sugimoto, and H Oribe, and A Ebihara
May 2023, Alternative therapies in health and medicine,
Y Kumagai, and A Fujimura, and H Nakashima, and T Shitoh, and K Sugimoto, and H Oribe, and A Ebihara
March 2000, International angiology : a journal of the International Union of Angiology,
Y Kumagai, and A Fujimura, and H Nakashima, and T Shitoh, and K Sugimoto, and H Oribe, and A Ebihara
April 2004, Yao xue xue bao = Acta pharmaceutica Sinica,
Y Kumagai, and A Fujimura, and H Nakashima, and T Shitoh, and K Sugimoto, and H Oribe, and A Ebihara
February 2012, BMC clinical pharmacology,
Y Kumagai, and A Fujimura, and H Nakashima, and T Shitoh, and K Sugimoto, and H Oribe, and A Ebihara
April 2004, Brain research,
Copied contents to your clipboard!